中国医学科学院学报

高级检索
中国医学科学院学报

中国医学科学院学报 ›› 2013, Vol. 35 ›› Issue (1): 64-68.doi: 10.3881/j.issn.1000-503X.2013.01.012

• 论著 • 上一篇    下一篇

甲状腺乳头状癌并BRAFV600E突变及原癌基因重排蛋白表达与其侵袭性的关系

孟超1,高洁2,梁军1,梁智勇2,林岩松3   

  1. 1青岛大学医学院附属医院肿瘤科,青岛 266003中国医学科学院 北京协和医学院 北京协和医院 2病理科 3核医学科,北京 100730
  • 收稿日期:2012-04-25 出版日期:2013-03-07 发布日期:2013-03-07
  • 通讯作者: 林岩松 电话:010-69155610,电子邮件:linyansong68@yahoo.com.cn E-mail:linyansong68@yahoo.com.cn
  • 基金资助:
    国家自然科学基金(30970850)和卫生行业科研专项项目(201202012)

Invasive Properties of Papillary Thyroid Cancer with Concurrent BRAFV600E Mutationand Rearranged during Transfection Proto-oncogene Protein Expression

MENG Chao1, GAO Jie2, LIANG Jun1, LIANG Zhi-yong2, LIN Yan-song3   

  1. 1Department of Oncology, the Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, China2Department of Pathology, 3Department of Nuclear Medicine, PUMC Hospital, CAMS and PUMC, Beijing 100730, China
  • Received:2012-04-25 Online:2013-03-07 Published:2013-03-07
  • Supported by:
    Supported by the National Natural Sciences Foundation of China (30970850)and the Research Special Fund of the Health Industry(201202012);第一、二位作者对本文贡献一致The first two authors contributed equally to this article

摘要: 目的 探讨BRAFV600E突变及原癌基因重排 (RET) 蛋白表达并存与甲状腺乳头状癌(PTC)侵袭性的关系。方法 收集50例PTC患者术后病理,分别用RT-PCR检测 BRAFV600E突变,免疫组织化学SP法检测RET表达情况。分析BRAFV600E突变合并RET表达组(n=24)和BRAFV600E单突变或RET单表达组 (n=19)的临床及病理特征。结果 BRAFV600E突变率、 RET表达率分别为76%(38/50)、56%(28/50),存在BRAFV600E突变合并RET表达者占48%(24/50)。与BRAFV600E突变合并RET表达组比较, BRAFV600E单突变或RET单表达组肿瘤组织分化程度差,且甲状腺癌评分系统评分较高(P=0.011,P=0.022)。结论 BRAFV600E突变并存RET表达时提示PTC肿瘤组织分化差、更易出现实体亚型等侵袭性较高的病理亚型,有可能增加肿瘤相关死亡风险。   

关键词: BRAFV600E突变, 原癌基因重排蛋白表达, 甲状腺乳头状癌, 侵袭性

Abstract: Objective To investigate the aggressive properties of papillary thyroid cancer (PTC) with concurrent BRAFV600Emutation and rearranged during transfection (RET) proto-oncogene protein expression. Methods Fifty pathologically confirmed PTC patients who had received thyroidectomy were enrolled in this study. BRAFV600E mutation was detected by real time polymerase chain reaction (RT-PCR), while RET protein expression was measured by immunohistochemical SP method. Clinical and pathological features were compared between the concurrent BRAFV600E mutation and RET protein expression group (n=24) and BRAFV600E mutation or RET protein expression alone group (n=19). Seven patients were ruled out from the final analysis due to the absence of either BRAFV600E mutation or RET protein expression. Results Of these 50 patients, BRAFV600E mutation and RET protein expression were detected in 38 patients (76%) and 28 patients (56%), respectively. Concurrent BRAFV600E mutation and RET expression was detected in 24 patients (48%). Compared with the concurrent BRAFV600E mutation and RET protein expression group, the BRAFV600E mutation or RET protein expression alone group had relatively poorer tissue differentiation and higher prognostic score (P=0.011, P=0.022). Conclusion PTC patients with concurrent BRAFV600E mutation and RET expression present poorer differentiation, more highly aggressive variant in carcinoma tissues, and higher cancer-related mortality risk.

Key words: BRAFV600E mutation, tyrosine kinase receptor protein expression, papillary thyroid cancer, aggressiveness

中图分类号: